Clinical trials: Coronavirus Disease-2019
Long COVID, Long Coronavirus Disease 2019 (Covid19)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Trial name
- NCT06305793
- Testing
- IVIG (intravenous immunoglobulin), Coordinated Care, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Kanecia Obie Zimmerman
Older Adults
The Effectiveness of Health Promotion Programs on the Pre-frail Individuals
This pilot study aimed to examine the efficacy of a home-based multicomponent exercise training program in older community- dwellers during to the Coronavirus Disease 2019.
- Trial name
- NCT05476471
- Testing
- multicomponent exercise training program
- Where
- Taiwan
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Shu-Hung Chang
Coronavirus, Coronavirus Infection
Convalescent Plasma for Patients With COVID-19: A Pilot Study
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases.
- Trial name
- CP-COVID-19 (NCT04332380)
- Testing
- Plasma
- Where
- Colombia
- Volunteers
- 10 people
- Sponsor
- Universidad del Rosario
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Covid19
Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study
online questionnaire will be distributed in different country to detect the oral change in patient diagnosed with COVID-19
- Trial name
- NCT04487665
- Volunteers
- 50 people
- Sponsor
- Cairo University
Healthy
Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Study to support the mental and physical well-being of US health care workers during the COVID-19 pandemic and ensure high-quality care for patients through Stress First Aid.
- Trial name
- COVER-HCW (NCT04723576)
- Testing
- Stress First Aid
- Where
- 2 sites in United States
- Volunteers
- 7,444 people, healthy volunteers welcome
- Sponsor
- RAND
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19.
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT04665115
- Testing
- Ibrutinib, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Academic and Community Cancer Research United
Mental Disorder
Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019
Background: Direct exposure to public health emergencies is associated with increased mental disorders. It is less clear about the prevalence of common mental disorders and its correlates in Chinese adolescents after experiencing…
- Trial name
- NCT04299711
- Testing
- Exposed to the novel coronavirus disease 2019
- Volunteers
- 3,428 people
- Sponsor
- University of Macau
Post-COVID-19
Sleep Characteristics in Post-COVID-19 Patients
After acute infection, patients with coronavirus disease 2019 (COVID-19) often suffer from persisting symptoms for more than 3 months (post COVID-19).
- Trial name
- NCT05124548
- Testing
- Sleep diagnostics
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Schön Klinik Berchtesgadener Land
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Coronavirus Disease 2019
Clinical Outcomes of Patients With COVID19
As of February 17th, 2020, China has 70635 confirmed cases of coronavirus disease 2019 (COVID-19), including 1772 deaths. Human-to-human spread of virus via respiratory droplets is currently considered to be the main route of…
- Trial name
- NCT04280913
- Testing
- retrospective analysis
- Where
- China
- Sponsor
- Guangzhou Institute of Respiratory Disease
COVID-19
A Phase II/III Study of Sargramostim
This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on…
- Trial name
- NCT04642950
- Testing
- Sargramostim
- Where
- 7 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Nobelpharma
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
COVID-19
Developing an Effective Intervention to Address Post-Corona-Virus-Disease-2019 Balance Disorders, Weakness and Muscle Fatigue in Individuals Aged 65+
The long-term consequences and sequelae of COVID-19 are still unclear; however, a vast number of elderly individuals have reported prolonged general weakness and muscular fatigue, leading to significant functional decline…
- Trial name
- NCT05934279
- Testing
- Resistance Training
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Józef Piłsudski University of Physical Education
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19, Pneumonia, Viral
Checkpoint Blockade in COVID-19 Pandemic
This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical trial
- Trial name
- COPERNICO (NCT04335305)
- Testing
- Tocilizumab, Pembrolizumab (MK-3475)
- Where
- 7 sites in Spain
- Volunteers
- 12 people
- Sponsor
- MedSIR